"Antiangiogenn\u00ED l\u00E9\u010Dba karcinomu ovaria"@cs . . "Epiteli\u00E1ln\u00ED n\u00E1dory ovaria, tuby nebo peritonea (epithelial ovarian cancer - EOC) vykazuj\u00ED podobn\u00E9 charakteristiky chov\u00E1n\u00ED. V\u00FDznamnou podm\u00EDnkou pro jejich v\u00FDvoj je zaji\u0161t\u011Bn\u00ED p\u0159\u00EDsunu krve pomoc\u00ED n\u00E1dorov\u00E9ho krevn\u00EDho \u0159e\u010Di\u0161t\u011B. Hlavn\u00EDm r\u016Fstov\u00FDm faktorem kontroluj\u00EDc\u00EDm n\u00E1dorovou angiogenezi je vaskul\u00E1rn\u00ED endotelov\u00FD r\u016Fstov\u00FD faktor (VEGF). Angiogeneze hraje z\u00E1sadn\u00ED roli v r\u00E1mci norm\u00E1ln\u00ED ovari\u00E1ln\u00ED fyziologie, v patogenezi epiteli\u00E1ln\u00EDch ovari\u00E1ln\u00EDch n\u00E1dor\u016F (EOC), progresi n\u00E1dorov\u00E9 masy a vzniku ascitu i v metastatick\u00E9m rozsevu. VEGF a jeho receptor VEGFR jsou exprimov\u00E1ny v bu\u0148k\u00E1ch EOC a jejich koncentrace se zvy\u0161uje v r\u00E1mci vzniku malign\u00EDho ascitu. To je d\u016Fvodem uva\u017Eovat o VEGF a jeho receptoru jako potenci\u00E1ln\u00EDch c\u00EDlech l\u00E9\u010Dby u EOC [1]."@cs . "CZ - \u010Cesk\u00E1 republika" . . "I" . . "Antiangiogenn\u00ED l\u00E9\u010Dba karcinomu ovaria"@cs . "Antiangiogenn\u00ED l\u00E9\u010Dba karcinomu ovaria" . "Antiangiogenic therapy for ovarian cancer"@en . . "RIV/00064165:_____/13:10209625" . "Epithelial tumours of the ovary, fallopian tube or peritoneum (epithelial ovarian cancer - EOC) manifest similar behavioral characteristics. An important condition for their development is the provision of blood supply through the tumour bloodstream. The main growth factor controlling the tumour angiogenesis is the vascular endothelial growth factor (VEGF). Angiogenesis plays an essential role within the normal ovarian physiology, pathogenesis of epithelial ovarian cancer (EOC), progression of tumour mass and arising of ascites also in metastatic dispersal. VEGF and its receptor VEGFR are expressed in the EOC cells and their concentration increases within the development of the malign ascites. This is the reason why VEGF and its receptor should be considered as the potential treatment targets in relation to the EOC [1]."@en . "Epiteli\u00E1ln\u00ED n\u00E1dory ovaria, tuby nebo peritonea (epithelial ovarian cancer - EOC) vykazuj\u00ED podobn\u00E9 charakteristiky chov\u00E1n\u00ED. V\u00FDznamnou podm\u00EDnkou pro jejich v\u00FDvoj je zaji\u0161t\u011Bn\u00ED p\u0159\u00EDsunu krve pomoc\u00ED n\u00E1dorov\u00E9ho krevn\u00EDho \u0159e\u010Di\u0161t\u011B. Hlavn\u00EDm r\u016Fstov\u00FDm faktorem kontroluj\u00EDc\u00EDm n\u00E1dorovou angiogenezi je vaskul\u00E1rn\u00ED endotelov\u00FD r\u016Fstov\u00FD faktor (VEGF). Angiogeneze hraje z\u00E1sadn\u00ED roli v r\u00E1mci norm\u00E1ln\u00ED ovari\u00E1ln\u00ED fyziologie, v patogenezi epiteli\u00E1ln\u00EDch ovari\u00E1ln\u00EDch n\u00E1dor\u016F (EOC), progresi n\u00E1dorov\u00E9 masy a vzniku ascitu i v metastatick\u00E9m rozsevu. VEGF a jeho receptor VEGFR jsou exprimov\u00E1ny v bu\u0148k\u00E1ch EOC a jejich koncentrace se zvy\u0161uje v r\u00E1mci vzniku malign\u00EDho ascitu. To je d\u016Fvodem uva\u017Eovat o VEGF a jeho receptoru jako potenci\u00E1ln\u00EDch c\u00EDlech l\u00E9\u010Dby u EOC [1]." . . "17" . . "Antiangiogenn\u00ED l\u00E9\u010Dba karcinomu ovaria" . . . "61351" . "[3FB218D96AB5]" . . . "RIV/00064165:_____/13:10209625!RIV14-MZ0-00064165" . "Antiangiogenic therapy for ovarian cancer"@en . . "1"^^ . . . "1"^^ . "http://www.prolekare.cz/linkout/40474" . "1" . . . "7"^^ . "VEGF; vascular endothelial growth factor; PGF; epithelial ovarian cancer; VEGF; ovarian cancer; Bevacizumab"@en . . "Praktick\u00E1 gynekologie" . . "Tesa\u0159ov\u00E1, Petra" . . "1211-6645" .